EGFR mutations underlie the responsiveness of NSCLC to gefitinib

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations

By Park In   Kim Jin   Jung Jae   Han Ji-Youn  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 791-799

Springer Publishing Company

Access to resources Recommend Favorite

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

By de Mello Ramon Andrade   Madureira Pedro   Carvalho Liliana S   Araújo António   O’Brien Mary   Popat Sanjay  

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1765-1777

Future Medicine

Access to resources Recommend Favorite

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

By  

Current Medicinal Chemistry, Vol. 9, Iss. 8, 2002-04 ,pp. : 879-891

Bentham Science Publishers

Access to resources Recommend Favorite